Are you seeing more children with type 2 diabetes in your practice? Follow the link to share your response.

Tobacco use is a well-established single most important preventable cause of disease and death. Healthcare providers are well-positioned to treat cigarette smoking and nicotine dependence among their patients. Unfortunately, not every physician, physician assistant, or nurse have sufficient time to provide extensive counseling and treatment during patient visits. QuitMedKit© is designed to assist healthcare providers in effective counseling and treatment of tobacco dependence among their patients. This program provides state-of-the-art knowledge on behavioral counseling and pharmacological treatments for nicotine dependence.

We all know the benefits of the newer insulins, i.e., faster action times, less peak from the long actings, etc. But the cost, more often than we know, can lead to patients decreasing insulin doses, doing without until the next payday, or doing without it altogether, as we’ve read about. …

Incretin defect: Oral glucose elicits a greater insulin response than does intravenous glucose. As first demonstrated by Nauck et al., when tested at matched plasma glucose concentrations (iso- glycemic protocol) the oral route of glucose administration induces a robust increment in insulin secretion as compared with the intravenous route. In nondiabetic subjects, such potentiation — named incretin effect — averages 50 – 70% with a standard (75 g) oral glucose load, and increases with the size of the glucose load. As depicted in Figure 24.10, the incretin effect is characteristically lost in patients with T2DM.

How much time do you spend with a patient newly diagnosed with type 2 diabetes,, even though you refer them for diabetes education? Follow the link to share your response.

 In part 2 of this 2-part Homerun Slides series, Finnish vs ADA diabetes risk scores. To download the complete set in PowerPoint format, just use this link: Prediabetes Part 2. Catch up on past Homerun Slides for the Hypertension Update: Prediabetes Part 1.

The dominance of beta-cell functional impairment: As discussed earlier, the available evidence indicates that an average 30% loss of beta-cells is present in the islets of patients with T2DM. However, based on a series of considerations it is unlikely that this beta-cell deficit alone is the cause of most cases of diabetes. First, in vivo assessment of beta-cell function consistently shows a greater than 50% reduction in patients with overt T2DM, a difference that is amplified when using intravenous glucose.

Administration releases “American Patient First” blueprint to lower drug prices, reduce out-of-pocket costs.

Glyburide versus subcutaneous insulin did not result in a greater frequency of perinatal complications.

Weight loss between young adulthood and midlife found to create statistically significant reductions in risk for diabetes.